Sign In
Buy ALXO
$1.67
-0.110 (-6.18%)
At Close: Jun 03, 2026
Is ALX Oncology Holdings (ALXO) Stock Outpacing Its Medical Peers This Year?
10:40am, Monday, 09'th Feb 2026
Here is how ALX Oncology Holdings Inc. (ALXO) and Amneal Pharmaceuticals (AMRX) have performed compared to their sector so far this year.
Corey Goodman Acquires 3,184,713 Shares of ALX Oncology (NASDAQ:ALXO) Stock
04:21am, Friday, 06'th Feb 2026
ALX Oncology Holdings Inc. (NASDAQ: ALXO - Get Free Report) Director Corey Goodman acquired 3,184,713 shares of the business's stock in a transaction on Monday, February 2nd. The shares were bought at
Market Today: Tech Slump, Google AI Spend, Bitcoin Slide
05:35pm, Wednesday, 04'th Feb 2026
Guru Stock PicksAzvalor Internacional FI has made the following transactions:Reduce in XMAD: PSG by 98.37%Sold out in BAAdd in XMAD: COL by 6.77%New position in A
ALX Oncology Announces Pricing of Underwritten Offering
08:30am, Friday, 30'th Jan 2026
SOUTH SAN FRANCISCO, Calif., Jan. 30, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology,” Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel thera
- Exploratory analysis from Phase 1b/2 breast cancer trial reinforces CD47 as a predictive biomarker for response, as previously observed in the ASPEN-06 trial in HER2-positive gastric cancer –
ALX Oncology Holdings Inc. (ALXO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
05:25pm, Thursday, 15'th Jan 2026
ALX Oncology Holdings Inc. (ALXO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
ALX Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference
11:00am, Thursday, 08'th Jan 2026
SOUTH SAN FRANCISCO, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology"; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies
- First patient dosed in Phase 2 ASPEN-09-Breast trial evaluating evorpacept in combination with trastuzumab and physician's choice of chemotherapy in HER2-positive metastatic breast cancer; interim a
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Given Average Rating of “Moderate Buy” by Brokerages
01:38am, Friday, 02'nd Jan 2026
ALX Oncology Holdings Inc. (NASDAQ: ALXO - Get Free Report) has been assigned an average rating of "Moderate Buy" from the seven ratings firms that are currently covering the company, Marketbeat Ratin
Short Interest in ALX Oncology Holdings Inc. (NASDAQ:ALXO) Expands By 32.0%
05:14am, Tuesday, 30'th Dec 2025
ALX Oncology Holdings Inc. (NASDAQ: ALXO - Get Free Report) was the recipient of a significant increase in short interest in December. As of December 15th, there was short interest totaling 1,047,613
- Combination of evorpacept plus rituximab and lenalidomide (R 2 ) generated complete responses (CR) in 92% of patients with untreated indolent non-Hodgkin lymphoma (iNHL) comparing favorably to an ap
ALX Oncology to Present at Upcoming Investor Conferences
11:00am, Tuesday, 18'th Nov 2025
SOUTH SAN FRANCISCO, Calif., Nov. 18, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline
ALX Oncology Holdings Inc. (ALXO) Q3 2025 Earnings Call Transcript
03:56pm, Friday, 07'th Nov 2025
ALX Oncology Holdings Inc. ( ALXO ) Q3 2025 Earnings Call November 7, 2025 8:30 AM EST Company Participants Jason Lettmann - CEO & Director Barbara Klencke Conference Call Participants John Mills - IC
ALX Oncology Reports Third Quarter 2025 Financial Results and Provides Corporate Update
08:15am, Friday, 07'th Nov 2025
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a
ALX Oncology (ALXO) Expected to Announce Earnings on Friday
01:02am, Thursday, 06'th Nov 2025
ALX Oncology (NASDAQ: ALXO - Get Free Report) is expected to be posting its Q3 2025 results before the market opens on Friday, November 7th. Analysts expect ALX Oncology to post earnings of ($0.37) pe
